10x Genomics (TXG) Change in Account Payables (2018 - 2025)
Historic Change in Account Payables for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to -$5.4 million.
- 10x Genomics' Change in Account Payables rose 5956.11% to -$5.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.1 million, marking a year-over-year increase of 3661.3%. This contributed to the annual value of -$2.1 million for FY2025, which is 3661.3% up from last year.
- Per 10x Genomics' latest filing, its Change in Account Payables stood at -$5.4 million for Q4 2025, which was up 5956.11% from -$196000.0 recorded in Q3 2025.
- In the past 5 years, 10x Genomics' Change in Account Payables ranged from a high of $10.9 million in Q1 2021 and a low of -$13.4 million during Q4 2024
- In the last 5 years, 10x Genomics' Change in Account Payables had a median value of -$210000.0 in 2022 and averaged $272250.0.
- In the last 5 years, 10x Genomics' Change in Account Payables soared by 176692.19% in 2021 and then plummeted by 133125.0% in 2023.
- Over the past 5 years, 10x Genomics' Change in Account Payables (Quarter) stood at -$1.1 million in 2021, then skyrocketed by 79.77% to -$224000.0 in 2022, then plummeted by 1331.25% to -$3.2 million in 2023, then tumbled by 317.9% to -$13.4 million in 2024, then skyrocketed by 59.56% to -$5.4 million in 2025.
- Its Change in Account Payables stands at -$5.4 million for Q4 2025, versus -$196000.0 for Q3 2025 and $6.0 million for Q2 2025.